These Houston startups and companies clock in as the top employers in the U.S.

best of the rest

MD Anderson Cancer Center is a top place to work in the U.S. and Texas. Photo by F. Carter Smith/courtesy of MD Anderson

Whose boss is doing something right in Houston? Forbes set out to find out.

New rankings from Forbes identified the top employers in Houston and beyond, and that included both bigger companies and the country’s best startup employers. In Houston, the startups ranked as top employers are:

No. 120 — Imbuit
No. 310 — Code Ninjas (Pearland)
No. 353 — Axiom Space
No. 462 — Liongard

When it comes to more traditional businesses, Dr. Pete Pisters, CEO of MD Anderson Cancer Center, continues his reign. He was named a top boss in 2021. Now, the cancer treatment facility/research center he leads has been named one of the best employers in a new report.

MD Anderson Cancer Center ranked No. 10 among the country’s best large employers in the country. Staffing some 22,000 employees, the world-renowned cancer center also landed at No. 25 in Forbes list of America's Best Employers in 2021.

Other Houston-area companies on the list include: Houston Methodist (No. 37), Waste Management (No. 245), Sysco (No. 314), Shell Oil (no. 361), Halliburton (No. 389), Schlumberger (No. 403), ExxonMobil (No. 440), and BP (No. 487).

Other Texas employers ranked among the best large employers in the U.S. are:

  • No. 10 — MD Anderson Cancer Center, Houston
  • No. 37 — Houston Methodist, Houston
  • No. 38 — H-E-B, San Antonio
  • No. 135 — USAA, San Antonio
  • No. 140 — Keller Williams Realty, Austin
  • No. 143 — Dell Technologies, Round Rock
  • No. 214 — Texas Tech University, Lubbock
  • No. 245 — Waste Management, Houston
  • No. 279 — University of Texas at Austin
  • No. 314 — Sysco, Houston
  • No. 318 — Daikin Industries, Waller (North American operations hub for manufacturing, marketing, research, R&D, and customer support)
  • No. 324 — Whole Foods Market, Austin
  • No. 361 — Shell Oil, Houston
  • No. 389 — Halliburton, Houston
  • No. 403 — Schlumberger, Houston
  • No. 440 — ExxonMobil, Houston
  • No. 487 — BP, Houston (North American headquarters)

Elsewhere in Texas, Dallas reigns as the capital of Texas when it comes to the best big and small employers, according to Forbes, which put University of Texas Southwestern Medical Center in Dallas at No. 9 among the country’s best large employers in the country and Dallas-based life insurance platform Bestow at No. 16 among the country’s best startup employers.

UT Southwestern isn’t the only Dallas-Fort Worth employer to pop up on the Forbes list of the best large employers. Richardson-based software company RealPage sits at No. 49; Dallas-based Southwest Airlines, No. 56; Plano-based Toyota North America, No. 253; Plano-based Cinemark, No. 370; Dallas-based Jacobs, No. 375; Dallas-based Topgolf, No. 394; Dallas-based Primoris Services, No. 399; Irving-based Fluor, No. 422; Dallas-based CBRE, No. 423; Irving-based McKesson, No. 429; Fort Worth-based American Airlines, No. 446; and Plano-based Keurig Dr Pepper, No. 483.

Dallas-based software company Slync.io, holding the No. 290 spot for best startups.

What follows are the other Texas employers ranked among the best startup employers in the country.

Austin

No. 104 — Apty
No. 121 — Homeward
No. 169 — SparkCognition
No. 186 — Outdoor Voices
No. 255 — Outdoorsy
No. 323 — ICON
No. 324 — The Zebra
No. 330 — TrustRadius
No. 335 — Innovetive Petcare (Cedar Park)
No. 387 — AlertMedia
No. 400 — Iris Telehealth
No. 410 — Wheel
No. 455 — Billd
No. 460 — Aceable
No. 470 — Shipwell

Forbes teamed up with data and research company Statista to develop the rankings of the best large employers and best startup employers.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston researchers develop dissolvable implant for targeted cancer drug delivery

cancer research

Researchers at Houston Methodist have developed a biodegradable implant that can be used to safely and consistently deliver drug treatments to tumors and then dissolve without the need for further surgery.

The implant is only the size of a grain of rice, but its potential is staggering. The biodegradable nanofibrous drug-eluting seed (b-NDES) works as a reservoir parked inside a soft tumor, where it can slowly release immune-stimulating drugs over time. This overcomes a consistent problem with drugs such as immune checkpoint inhibitors. Normal systemic administration sees comparatively little of the drug making its way to the tumor, with most of it circulating throughout the body. The b-NDES is like deploying a small guerrilla fighting force embedded in enemy territory, doing maximum damage to the entrenched tumor.

"To improve cancer treatment, we're trying to start a fire inside the tumor itself," Corrine Chua, associate professor in the Center for BioNanoengineering at Houston Methodist Research Institute, said in a news release. "By activating immune cells directly within the tumor microenvironment, those cells can then travel throughout the body and seek out cancer wherever it exists. The b-NDES platform was developed to help keep therapeutic drugs concentrated inside tumors while minimizing exposure to healthy tissues.”

Chua co-led the study with Alessandro Grattoni, chair and director of the Center for BioNanoengineering at Houston Methodist Research Institute.

The study included support from the Nancy Owens Breast Cancer Foundation and the National Institutes of Health/National Cancer Institute.

Chau and Grattoni used preclinical models of triple-negative breast cancer, an aggressive form of cancer that is estrogen receptor-negative, progesterone receptor-negative and HER2-negative. Because of the receptor negativity, some popular treatments like tamoxifen and trastuzumab are ineffective. Chemotherapy has been shown to be the best course of action.

The b-NDES implant is deployed alongside radiation drugs. It keeps the drugs focused on the tumor, reducing the amount of harmful side effects typically seen when drugs are circulated more widely in the body. In 60 percent of the models, tumors were eliminated and did not cause side effects beyond the tumor site. Once the drugs have been deployed, the implant breaks down naturally.

While promising, more research will have to be done to expand use to other tumor types.

"Although the study focused on triple-negative breast cancer models, the approach could have broader applications for solid tumors," Grattoni added in the release. "It could potentially be used in cancers where there is a tumor lesion accessible for placement, including pancreatic or lung cancers."

New Houston platform Same Day Reels launches for on-demand content creation

In The Moment

If an event doesn't happen on Instagram, did it even really happen? In today's social media-driven age of branding and audience engagement, the answer increasingly is no.

Houston entrepreneur Karen De Amat is looking to fill the online content creation needs of companies with her new venture, Same Day Reels, which launched in early August. It will serve as a platform to connect companies and brands with talent that can help turn an event into a viral moment as it is happening.

"Events move quickly, and social media moves even faster,” said De Amat. “Same Day Reels was built to help brands capture the moment while it still matters. We are creating a more efficient way for businesses and creators to work together. Brands need content faster, and creators need more opportunities to turn their talent into real work. Same Day Reels brings those needs together.”

The company is focused on adding livestreams and concurrent short video content to "activations, launches, fundraisers, grand openings, conferences, hospitality experiences, and private celebrations." Such content can significantly increase the visibility of a product or brand according to digital marketing brands like Wyzowl, whose data found 63 percent of people in 2026 prefer to learn about new products via short video.

Packages offered by Same Day Reels will include filming, editing, and publishing content within hours of the targeted event.

De Amat says that her content creation platform will be a way to preserve the excitement of events and launches by enshrining them with immediate social media-driven memories.

“Event content is no longer just something you post after the fact,” De Amat said. “It is part of how people experience, remember and share the moment.”

Previously, De Amat is also the founder and CEO of Social Behavior, an influencer marketing company she launched from her home in 2014. It quickly garnered an array of clients and thrust De Amat into the spotlight, including numerous appearances on Fox 26's The Isiah Factor. Influencer Marketing Hub named her one of the top CEOs of influencer marketing companies in Houston in 2025.

---

This article originally appeared on CultureMap.com.

Bristol Myers Squibb to build $2.3B Houston pharma manufacturing campus

coming soon

New Jersey-based pharmaceutical giant Bristol Myers Squibb Co. has officially named Houston as the home of its new state-of-the-art manufacturing site.

The 60,000-square-foot facility represents a $2.3 billion investment, according to a news release. It is expected to create 500 skilled jobs and will be located in Houston's Generation Park.

BMS first announced that it was considering Houston among 16 other cities for the facility in May. The new hub will manufacture small molecule, biologic and antibody-drug conjugates and is part of a $40 billion commitment to invest in the United States over five years. Construction is slated to begin next year, with the facility coming online in 2030.

"We're building the domestic manufacturing capabilities needed to deliver the next generation of medicines and support future scientific breakthroughs. Houston and the state of Texas offer the talent, infrastructure, and partnership needed to help bring that vision to life," Christopher Boerner, CEO and board chair of BMS, said in the release.

The new facility will feature a modular, multi-modal design, which will allow the company to reconfigure and add to its manufacturing capabilities over time. BMS says it expects the facility to "(grow) in scale and capability well beyond its opening configuration."

"Our decision to build this state-of-the-art manufacturing campus in Houston, Texas, reflects our confidence in the region’s ability to support a world-class, digitally advanced supply operation,” Karin Shanahan, EVP and chief supply chain and operations officer of BMS, added in the release. “This facility is designed to deliver the speed, quality, and reliability that patients depend on, combining flexible, modular manufacturing with advanced digital capabilities to ensure consistent supply across multiple modalities. It strengthens our ability to operate with resilience and positions us to reliably deliver medicines to patients today while adapting future demands.”

Texas Gov. Greg Abbott shared that the state has granted BMS a $4.89 million Texas Enterprise Fund (TEF) grant for the project. TEF grants, administered by the Texas Economic Development & Tourism Office, support business relocation or expansion projects that create "new, good-paying jobs in the community and attract significant new capital investment to the state." The development is also a qualified project under the Texas Jobs, Energy, Technology, and Innovation (JETI) program.

“Texas is a global hub for life sciences, where today’s innovations shape the future of healthcare,” Abbott said in a news release. “This $2.3 billion investment by Bristol Myers Squibb in the dynamic biotech ecosystem in Houston is a testament to the depth of our skilled workforce and the pipeline of talent coming through our nation-leading technical colleges and research universities. With lower operating costs and easy access to markets across the U.S. and the world, Texas drives affordability for consumers.”

"Bristol Myers Squibb’s announcement is a tremendous win for Texas and the Houston region, further reinforcing our position as a premier destination for life sciences and advanced manufacturing,” added Greater Houston Partnership President and CEO Steve Kean.

Last fall, Eli Lilly and Co. selected Generation Park, a 4,300-acre, master-planned commercial district near Lake Houston, for its $6.5 billion manufacturing plant. More than 300 locations in the U.S. competed for the factory. Read more here.

View All Listings